Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis

Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis

Objective: Kanglaite(KLT), a type of Chinese medicine preparation, is considered as an adjuvant therapeutic option for malignant cancer treatment. This study aimed to systematically investigate the efficacy and safety of the combination of KLT and epidermal growth factor receptor-tyrosine kinase inh...

Full description

Bibliographic Details
Main Authors: Fanming Kong, Chaoran Wang, Xiaojiang Li, Yingjie Jia
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Pharmacology
Subjects:
EGFR-TKI
kanglaite
NSCLC
meta-analysis
stage III/IV
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.739843/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.739843/full

Similar Items